SPONSOR
iRegene Therapeutics Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 1
NCT06608355 Phase 1
Recruiting
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
Early-onset Parkinson's Disease
NCT07102342 Phase 1
Recruiting
This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
Parkinson Disease